abstract |
Tumor cells often evade the immune response, for example, through reduction or elimination of MHC expression and/or IFN-signaling, so uncontrolled proliferation may be possible. In the present invention, we demonstrate that antibody-based immunotherapy in combination with administration of IL2 is an effective therapy for these resistant tumors. More specifically, the present invention provides a subject a. a polynucleotide encoding a polypeptide comprising IL2 or a functional variant thereof or a polypeptide comprising IL2 or a functional variant thereof; and b. A method of treating a subject having a cancer that is at least partially resistant to an MHC-dependent T cell response comprising administering antibody-based immunotherapy. |